Dr. Lon S. Schneider, professor of psychiatry, neurology, and gerontology at the University of Southern California, has great news about patients in a two-year trial for Alzheimer’s. A new drug from the maker Eli Lilly has been monitoring 272 patients with brain scans indicative of Alzheimer’s disease.
This study has been monitoring patients whose scans did not diagnose or have symptoms of Alzheimer’s. Participants who received the drug has a 32 percent deceleration in the rate of decline. In six to twelve months, plaques were gone and stayed gone.
Read the full article titled Alzheimer’s Drug Shows Promise in Small Trial at nytimes.com.